GlassScriptPhysician profile
Catherine C Tan
NPI 1508886219
$4,115.40
in general payments reported to CMS, 2019-2025
26 companies · $833 in 2025
The $833 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $293 · 2021: $577 · 2022: $430 · 2023: $751 · 2024: $690 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,407.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $935.30 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $309.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $205.79 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Botanix Sb INC | $163.23 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $105.15 | 2019-2024 | Xarelto |
| Abbott Laboratories | $104.41 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $92.51 | 2020-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $88.03 | 2019-2024 | Breztri, Airsupra |
| Phathom Pharmaceuticals, INC. | $77.26 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.07 | 2019-2024 | Synjardy, Jardiance |
| Novartis Pharmaceuticals Corporation | $73.62 | 2019-2024 | |
| Leo Pharma INC. | $68.99 | 2025 | Adbry |
| Lilly USA, LLC | $61.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.86 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $42.13 | 2019-2020 | |
| Astellas Pharma US INC | $37.59 | 2021-2025 | Veozah |
| Seqirus USA INC | $37.09 | 2023-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Insulet Corporation | $31.42 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.73 | 2025 | Dupixent |
| Allergan, INC. | $27.64 | 2019-2020 | |
| Smith+Nephew, INC. | $25.28 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.73 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $20.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.60 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.